Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Show more
Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024...
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -4.56852791878 | 1.97 | 2.275 | 1.88 | 1285345 | 2.08999617 | CS |
4 | 0.25 | 15.3374233129 | 1.63 | 2.275 | 1.28 | 1095557 | 1.81330158 | CS |
12 | -0.09 | -4.56852791878 | 1.97 | 2.29 | 1.22 | 1177101 | 1.77395064 | CS |
26 | -2.83 | -60.08492569 | 4.71 | 4.805 | 1.22 | 1459482 | 2.51889962 | CS |
52 | 0.61 | 48.031496063 | 1.27 | 6.2801 | 1.065 | 1800015 | 2.7511222 | CS |
156 | -7.96 | -80.8943089431 | 9.84 | 10.06 | 0.8014 | 2050750 | 3.61785822 | CS |
260 | 0.18 | 10.5882352941 | 1.7 | 29.09 | 0.8014 | 1586348 | 6.47550815 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.